Short-term treatment with glucosamine hydrochloride specifically downregulates hypoxia-inducible factor-1α at the protein level in YD-8 human tongue cancer cells

JEONG-RANG JO*, YU-KYOUNG PARK† and BYEONG-CHURL JANG

Department of Molecular Medicine, College of Medicine, Keimyung University, Dalseo-gu 704-701, Republic of Korea

Received December 14, 2013; Accepted February 4, 2014

DOI: 10.3892/ijo.2014.2336

Abstract. Hypoxia-inducible factor-1 (HIF-1) is a tumor angiogenic transcription factor composed of an α and β subunit. We investigated the effect of glucosamine hydrochloride (GS-HCl) on the expression of HIF-1α and HIF-1β in serum-treated YD-8 human tongue cancer cells. While long-term (24 h) treatment with GS-HCl strongly repressed the expression of HIF-1α and HIF-1β at both the protein and mRNA levels, short-term (4 h) GS-HCl treatment inhibited HIF-1α at the protein level. Short-term GS-HCl treatment also decreased phosphorylation of p70S6K and S6, translation-related proteins. However, the results of subsequent pharmacological inhibition and protein stability analyses indicated that HIF-1α protein downregulation induced by short-term GS-HCl treatment was not through modulation of the mTOR/p70S6K/S6 signaling pathways, the 26S proteasomal and lysosomal activities and HIF-1α protein stability. Importantly, our further analyses identified that HIF-1α protein downregulation induced by short-term GS-HCl treatment was blunted by exogenous administration of the citric acid cycle metabolites citrate and 2-oxoglutarate, but not the glycolytic end products pyruvate and lactate. These findings demonstrate firstly that short-term GS treatment selectively downregulates HIF-1α at the protein level in YD-8 cells via interference of production of the citric acid cycle metabolites. It is proposed that short-term GS-HCl exposure may be applied for the treatment of oral tumors with high expression of HIF-1α.

Introduction

Glucosamine (GS) is an amino sugar and has been widely used as an alternative regimen for joint-related disease, such as rheumatoid arthritis and osteoarthritis. Many in vivo studies have implicated that GS has preventive actions on adjuvant arthritis in rats (1) and significant symptom-modifying effects on osteoarthritis in human clinical trials (2). In addition, results from many in vitro studies have shown that GS inhibits expression and/or activity of many inflammatory mediators, including cyclooxygenase-2, inducible nitric oxide synthase, matrix metalloproteases and nuclear factor-κB (NF-κB) (3,4), which further support its anti-inflammatory activity. Moreover, evidence clearly suggests that GS has strong anticancer effects. For instance, it has been previously shown that GS inhibits tumor growth (5,6). We and other investigators also have demonstrated the ability of GS to induce apoptosis in human cancer cells, such as prostate (DU145), breast (MDA-MB-231), leukemia (K562), glioma (U87MG) and tongue (YD-8) (7-12). Moreover, it is suggested that the mechanisms underlying GS-mediated anti-proliferative and pro-apoptotic effect on cancer cells may include translocation of cathepsin D and downregulation of B-cell lymphoma-extra large (8), inhibition of p70S6 kinase (p70S6K) (9) and signal transducer and activator of transcription-3 (STAT-3) (10), induction of autophagy via the stimulation of endoplasmic reticulum (ER) stress (11), and activation of caspases via the intrinsic pathway (12). In recent studies, we and other investigators have also demonstrated the ability of GS to inhibit expression of HIF-1α, a tumor angiogenic transcription factor in YD-8 tongue cancer cells (12) and in DU145 prostate cancer cells (13), which may support its antitumor property.

HIF-1 protein is composed of an α and a β subunit (14). In most cells, while expression of HIF-1α protein is differentially regulated under normoxic and hypoxic condition, HIF-1β protein is constitutively expressed regardless of oxygen tension (15). Indeed, numerous studies have demonstrated that under normoxia HIF-1α protein is unstable and rapidly degraded via the 26S proteasome-dependent protein degradation pathway, but HIF-1α protein, under hypoxia, is stable and the stable HIF-1α binds to HIF-1β (16-19). The HIF-1α/β dimeric complex then localizes to the nucleus where
the dimeric complex mediates the transcriptional induction of hypoxia responsive element containing genes that encode products involved in the hypoxic adaptation and/or new blood vessel formation (15). However, there is increasing body of evidence suggesting the hypoxia-independent upregulation of HIF-1α expression. For instance, it is shown that a number of factors, including serum, interleukin-1β, insulin, manganese, and ginsenoside-Rg1, induces expression of HIF-1α through transcriptional and/or translational upregulation in many types of cells under normoxia (13,20-23). Evidence also strongly suggests that activities of many intracellular signaling proteins, such as phosphoinositide 3-kinase, extracellular-regulated protein kinase-1/2, c-jun N-terminal kinase-1, S6, p38 mitogen-activated protein kinase, epidermal growth factor receptor/p70S6K, protein kinase B/mammalian target of rapamycin-p70S6K, and mTOR/p70S6K/S6, are necessary for normoxic induction of HIF-1α expression in response to extracellular stimuli (22,24-28).

Little is known about regulation of HIF-1α and HIF-1β expressions by GS in cancer cells. In this study, we investigated whether GS treatment for long-term (24 h) or short-term (4 h) period differentially regulates expression of HIF-1α and HIF-1β in serum-treated YD-8 human tongue cancer cells under normoxic condition and if any, determined the molecular and/or cellular mechanisms involved.

Materials and methods

Materials. RPMI-1640 medium, fetal bovine serum (FBS), and penicillin-streptomycin were purchased from Welgene (Daegu, Korea). Primary antibodies: mouse monoclonal anti-human HIF-1β, rabbit polyclonal anti-human p-p70S6K (Santa Cruz Biotechnology, Delaware, CA, USA), rabbit polyclonal anti-human p-S6 (Cell Signaling Technology, Beverly, MA, USA), rabbit polyclonal anti-human p-eIF-2α (Epitomics, Burlingame, CA, USA), and mouse monoclonal anti-human HIF-1α (BD Bioscience, San Jose, CA, USA) were purchased from the indicated companies. Secondary antibodies: goat anti-rabbit IgG-HRP and goat anti-mouse IgG-HRP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ECL western detection reagents were purchased from Thermo Scientific (Waltham, MA, USA). Bradford reagent was bought from Bio-Rad (Hercules, CA, USA). Plasticware, including 6-well plates, was purchased from SPL Life Sciences (Gyeonggi-do, Korea). Other reagents, including GS-HCl, were purchased from Sigma (St. Louis, MO, USA).

Cell culture. YD-8 human tongue cancer cells (Korean Cell Line Bank, Seoul, Korea) were grown at 37°C in a humidified condition of 95% air and 5% CO₂ in RPMI-1640 supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin.

Preparation of whole cell lysates. To see the effect of GS-HCl on phospho-specific and/or total expression levels of a variety of cellular proteins, including HIF-1α, HIF-1β, p70S6K, S6 and eukaryotic translation initiation factor-2α (eIF-2α), YD-8 cells (0.5x10⁶/2 ml/well) were seeded in 6-well plates the day before GS-HCl treatment. Cells were treated without or with different concentrations of GS-HCl for 4 or 24 h. Control or GS-HCl-treated cells were then washed twice with PBS and exposed to cell lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.25% sodium deoxycholate, 1% Triton X-100, 1% Nonidet P-40, 1 mM EDTA, 1 mM EGTA, proteinase inhibitor cocktail (IX)]. The cell lysates were collected in a 1.5 ml tube and centrifuged for 20 min at 4°C at 12,000 rpm. The supernatant was saved and protein concentrations were determined with Bradford reagent.

Western blot analysis. Proteins (50 µg) were separated by SDS-PAGE (10%) and transferred onto nitrocellulose membranes (Millipore, Billerica, MA, USA). The membranes were washed with TBS (10 mM Tris, 150 mM NaCl) supplemented with 0.05% (vol/vol) Tween-20 (TBST) followed by blocking with TBST containing 5% (wt/vol) non-fat dried milk. The membranes were incubated overnight with antibodies specific for p-p70S6K (1:2,000), p-S6 (1:2,000), HIF-1α (1:1,000), HIF-1β (1:1,000), eIF-2α (1:1,000) or actin (1:5,000) at 4°C. The membranes were then exposed to secondary antibodies coupled to horseradish peroxidase for 2 h at room temperature. The membranes were washed three times with TBST at room temperature. Immunoreactivities were detected by ECL reagents. Equal protein loading was assessed by the expression level of actin protein.

Reverse transcription-polymerase chain reaction (RT-PCR). To see the effect of GS-HCl on mRNA expression of HIF-1α, HIF-1β or actin, YD-8 cells (0.5x10⁶/2 ml/well) was seeded in 6-well plates the day before GS-HCl treatment. Cells were treated without or with different concentrations of GS-HCl for 4 or 24 h. Total cellular RNA from control or GS-HCl-treated cells was isolated with the RNaZol-B (Tel-Test, Friendswood, TX, USA). Total RNA (3 µg) was reverse transcribed using a random hexa-deoxynucleotide primer and reverse transcriptase. Single stranded cDNA was amplified by PCR with the following primers. The sequences of the respective primer are: HIF-1α sense, 5’-CTCAAAGTCCGGACGCCTCATA-3’; HIF-1α anti-sense, 5’-CTCAAGGTTGGGGTTGTCTG-3’; HIF-1β sense, 5’-GTG CGCACACATGCTCTTGAT-3’; HIF-1β anti-sense, 5’-CTTTAT GGCCAAGTCTCGGGT-3’; actin sense, 5’-CTCAAAGTCGGACAGCCTCATA-3’; actin antisense, 5’-CTTTAT GGCCAAGTCTCGGGT-3’. The PCR conditions applied were: HIF-1α, 25 cycles of denaturation at 95°C for 30 sec, annealing at 59°C for 30 sec, and extension at 72°C for 30 sec; HIF-1β, 25 cycles of denaturation at 95°C for 30 sec, annealing at 56°C for 30 sec, and extension at 72°C for 30 sec; actin, 25 cycles of denaturation at 95°C for 30 sec, annealing at 56°C for 30 sec, and extension at 72°C for 30 sec. Expression levels of actin mRNA was used as an internal control to evaluate the relative mRNA expression of HIF-1α and HIF-1β.

Measurement of HIF-1α protein stability. To determine the stability of HIF-1α protein in control or GS-HCl-treated YD-8 cells, YD-8 cells (0.5x10⁶ cells in 2 ml/well in a 6-well plate) were primarily grown in culture medium containing serum (10% FBS) for 4 h under normoxic condition to induce high cellular levels of HIF-1α protein. Cells were then treated for an additional 0.25, 0.5 or 1 h without or with GS-HCl in the presence of CHX, a translation inhibitor, to block ongoing translation. Each time, whole cell lysates were prepared and
subjected to immunoblot analysis for HIF-1α or actin to measure the amounts of HIF-1α protein remaining in the cells. Actin was used as an internal control to relatively compare the level of HIF-1α remaining in the cells.

Results

Time-differential regulation of HIF-1α and HIF-1β expressions in YD-8 cells by GS-HCl. Initially, we investigated whether GS-HCl treatment for short-term (4 h) or long-term (24 h) period differentially regulates expressions of HIF-1α and HIF-1β in YD-8 cells grown in culture media containing serum (10% FBS) under normoxia. As shown in Fig. 1A and B, compared with control (lane 1), long-term GS-HCl treatment led to a concentration-dependent downregulation of HIF-1α at the both protein and mRNA levels (lanes 2-4). However, there was also a dose-dependent reduction of HIF-1β protein and mRNA expressions by long-term GS-HCl treatment. As shown in Fig. 1C and D, compared with control (lane 1), short-term GS-HCl treatment also led to a concentration-dependent downregulation of HIF-1α protein (lanes 2-4). Short-term GS-HCl treatment at the doses tested, however, did not affect expression of HIF-1α mRNA, HIF-1β protein and HIF-1β mRNA. Control actin protein or mRNA expression remained constant under these experimental conditions (Fig. 1).

Short-term GS-HCl treatment induces change of the phosphorylation levels of p70S6K, S6 and elf-2α in YD-8 cells. Considering that short-term GS-HCl treatment inhibits HIF-1α at protein, but not mRNA, level (Fig. 1C and D), we next determined the effect of short-term GS-HCl treatment on activities of translation-related signaling proteins, herein p70S6K, S6 and elf-2α, in YD-8 cells. As shown in Fig. 2A, in the absence of GS-HCl, there were high levels of phosphorylated p70S6K and S6 while no or weakly phosphorylated eIF-2α in YD-8 cells cultured for 2 or 4 h in media containing serum under normoxia (lane 1 or 3). Notably, short-term (2 or 4 h) treatment with GS-HCl decreased the amounts of phosphorylated p70S6K and S6 but increased the levels of phosphorylated eIF-2α (lane 2 or 4). Rapamycin is an inhibitor of mTOR kinase complex, a master regulator of protein translation and has been shown to inhibit phosphorylation and activation of the mTOR and its downstream targets, p70S6K and S6 (26,29). Using rapamycin, we next investigated whether HIF-1α protein downregulation by short-term GS-HCl treatment is due to inhibition of mTOR/p70S6K/S6 signals. As shown in Fig. 2B, while short-term (2 or 4 h) GS-HCl treatment that largely blocked S6 phosphorylation (top panel, lane 2 or 5) strongly suppressed HIF-1α protein expression (middle panel, lane 2 or 5), treatment with rapamycin for 2 or 4 h that completely inhibited S6 phosphorylation (top panel, lane 3 or 6) had no effect on expression of HIF-1α protein (middle panel, lane 3 or 6). Control actin protein expression remained constant under these experimental conditions (Fig. 2A and B).
The inhibitory effect of short-term GS-HCl treatment on HIF-1α protein expression in YD-8 cells is the 26S proteasome- and lysosome-independent. Cellular expression of a protein is largely influenced by the protein degradation. Protein degradation is often mediated through the 26S proteasome- and lysosome-mediated proteolytic pathways. Using MG132, the 26S proteasome inhibitor or chloroquine (CQ), the lysosomal inhibitor, we next questioned whether the HIF-1α protein downregulation induced by short-term GS-HCl treatment is linked to the 26S proteasome and/or lysosome pathways in YD-8 cells. As shown in Fig. 3A, the inhibitory effect of short-term GS-HCl treatment on HIF-1α protein expression (lane 4) was largely blocked by MG132 (lane 5), but not CQ (lane 6). However, it was found that single treatment with MG132 for 4 h was enough to strongly increase expression of HIF-1α protein (lane 2). Single treatment with CQ for 4 h had no enhancing effect on expression of HIF-1α protein (lane 3). As shown in Fig. 3B, HIF-1α mRNA expression remained unchanged by 4 h treatment without or with GS-HCl in the absence or presence of MG132 (lanes 1-4). Control actin protein or mRNA expression was not affected under these experimental conditions (Fig. 3A and B).

The inhibitory effect of short-term GS-HCl treatment on HIF-1α protein expression in YD-8 cells is not due to alteration of HIF-1α protein stability. Cellular expression of a protein is largely influenced by the protein stability. Cycloheximide (CHX) is a translation inhibitor and has been widely used as a key biochemical agent in determining the stability of a protein. Using CHX, we further determined whether HIF-1α protein downregulation induced by short-term GS-HCl treatment is associated with change of HIF-1α protein stability. As shown in Fig. 4, in the presence of CHX, there was a sharp decline of the amounts of HIF-1α protein remained in YD-8 cells (lanes 2-4), suggesting that when translation is blocked by CHX, HIF-1α protein is unstable and rapidly degraded in the cells. However, the rapid degradation of HIF-1α protein was not further enhanced or accelerated in the presence of GS-HCl at the times tested. Control actin protein expression remained constant under these experimental conditions (Fig. 4).

The inhibitory effect of short-term GS-HCl treatment on HIF-1α protein expression in YD-8 cells is blunted by exogenous supplementation of the citric acid cycle intermediates (citrate, 2-oxoglutarate), but not the glycolytic end products (pyruvate, lactate). GS is a glucose deprivation mimetic and thus an inhibitor of glycolysis. It is thus suggested that 4 h exposure of GS into YD-8 cells may interfere with glucose metabolism, which may lead to no or less production of the byproducts of glucose metabolism. Using exogenous supplementation of a number of glucose metabolites, including lactate, pyruvate (the glycolytic end products), citrate and 2-oxoglutarate (the citric acid cycle intermediates), we next investigated whether HIF-1α protein downregulation by short-term GS-HCl treatment is linked to the ability of GS-HCl to interfere with glucose metabolism pathway. As shown in Fig. 5A or B, compared with control (lane 1), single administration of pyruvate or lactate did not affect expression of HIF-1α protein (lane 2). Furthermore, HIF-1α protein downregulation by short-term GS-HCl treatment (lane 3) was not blocked by addition of pyruvate or lactate (lane 4). Notably, as shown in Fig. 5C, though single administration of citrate did not affect expression of HIF-1α protein (lane 2), the inhibitory effect of short-term GS-HCl treatment on HIF-1α protein expression (lane 3) was in part blunted by addition of citrate (lane 4). Of further note, as shown in Fig. 5D, compared with control (lane 1), single administration of 2-oxoglutarate largely increased (enhanced) expression of HIF-1α protein (lane 2), HIF-1α protein downregulation by short-term GS-HCl treatment (lane 3) was not shown in the presence of 2-oxoglutarate (lane 4).

The specificity of short-term GS-HCl treatment to inhibit expression of HIF-1α protein in YD-8 cells. To evaluate the specificity, we next compared the effect of short-term (4 h)
treatment of GS-HCl and other salt form or derivative of GS, herein GS-sulfate or N-acetyl GS, on expression of HIF-1α protein in YD-8 cells. As shown in Fig. 6, short-term (4 h) treatment with GS-HCl led to strong inhibition of HIF-1α protein expression (lane 2), but treatment with GS-sulfate or N-acetyl GS for 4 h did not affect expression of HIF-1α protein (lane 3 or 4).

Discussion

HIF-1 is a tumor angiogenic transcription factor composed of an α and β subunit and is regarded an interesting therapeutic target in cancer biology. Little is known about regulation of HIF-1α and HIF-1β expressions by GS-HCl in cancer cells. Here, we report for the first time that short-term GS-HCl treatment selectively downregulates HIF-1α at protein level in YD-8 cells through interference of production of the citric acid cycle intermediates.

Expression of HIF-1α is regulated at multiple steps, including transcription, translation and/or post-translation (17,19,22,30,31). The present study demonstrates that GS-HCl inhibits expression of HIF-1α at the protein and mRNA levels in YD-8 cells in the time differentially. We have shown that long-term GS treatment with GS-HCl (10 mM) inhibits expression of HIF-1α at both protein and mRNA levels in YD-8 cells (Fig. 1A and B), suggesting HIF-1α transcriptional downregulation. However, considering the present findings that short-term GS-HCl treatment inhibits HIF-1α at protein level (Fig. 1C), but it does not influence HIF-1α mRNA expression (Fig. 1D) and protein stability (Fig. 3C) in YD-8 cells, it is likely that short-term GS-HCl treatment represses HIF-1α protein expression via inhibition of translational process and/or cellular accumulation of the protein. Aforementioned, HIF-1β is shown to be ubiquitously expressed in most types of cells regardless of oxygen tension. We have herein shown that HIF-1β mRNA and protein are substantially expressed in YD-8 cells under normoxic condition (Fig. 1), indicating that expression of HIF-1β is controlled at the levels of transcription and translation. In this study, however, we show that long-term GS-HCl treatment inhibits expression of HIF-1β by transcriptional downregulation while short-term GS-HCl treatment does not influence expression of HIF-1β at protein and mRNA levels, which may further strengthen the specificity of short-term GS-HCl treatment to inhibit expression of HIF-1α protein in YD-8 cells.

Previously, studies have demonstrated the importance of activities of a number of intracellular signaling proteins and/or translation-related proteins in normoxic upregulation of HIF-1α protein in response to extracellular stimuli (22,24-28). Among these, S6 is a ribosomal protein involved in translation (32). S6 is shown to be phosphorylated and activated by the action of an upstream protein kinase p70S6K (33). Moreover, there is evidence that PI3K/PKB and mTOR are upstream kinases
responsible for S6K phosphorylation and activation (34). Of interest, there are studies demonstrating GS-HCl regulation of S6K signaling pathway. For instance, it is shown that 24 h treatment with GS-HCl (5 mM) inhibits the activity of S6K in DU145 prostate cancer cells and MDA-MB-231 breast cancer cells and the inhibition is important for GS-HCl-induced anti-proliferative effects on these cancer cells (9). The same group also has addressed that 10 h treatment with GS-HCl (5 mM) inhibits S6K signaling pathway and importantly the inhibition is in part linked to inhibition of HIF-1α at protein level in serum-treated DU145 cells (13). In the present study, we have shown that short-term (2 or 4 h) treatment with GS-HCl (10 mM) largely blocks phosphorylation of not only S6K but also S6 in YD-8 cells (Fig. 2A). However, as deduced from results of pharmacological inhibition studies herein that treatment with rapamycin, an mTOR/S6K/S6 that completely blocks S6 phosphorylation does not influence HIF-1α protein expression in YD-8 cells (Fig. 2B), it appears that no link exists between HIF-1α protein downregulation and inhibition of mTOR/S6K/S6 signaling pathway in YD-8 cells in response to short-term GS-HCl exposure. elf-2-α is another translational regulatory protein (35). It has been shown that phosphorylation (on Serine 51) of elf-2-α by stress kinases, such as protein kinase R, leads to its inactivation and inhibition of global translation (36). There are previous studies stating that GS inhibits protein, mRNA, DNA synthesis in mouse leukemic cells L5178Y, which may contribute to its antitumor effect (6,7). However, it has been shown that short-term (2 h) treatment with GS-HCl (2 or 5 mM) does not affect global protein synthesis in DU145 cells (13). In this study, we demonstrated that short-term (2 or 4 h) GS-HCl treatment increased phosphorylated forms of elf-2-α in YD-8 cells (Fig. 2A), raising the possibility that short-term GS-HCl treatment may inactivate elf-2-α leading to inhibition of global translation in the cells. However, the present findings that short-term GS-HCl treatment does not affect expression of other proteins, herein HIF-1β and actin, in YD-8 cells (Fig. 1C and D), and there is no difference of the amounts of total protein in control or GS-HCl (4 h)-treated YD-8 cells (data not shown) suggest that though there is elf-2-α inactivation, short-term GS-HCl treatment does not induce inhibition of global translation and HIF-1α protein downregulation seems to be not a part of inhibition of global translation, but a selective event triggered by short-term exposure of this amino sugar in YD-8 cells.

Increasing evidence suggests that degradation of HIF-1α at protein level is largely associated with the 26S proteasome-mediated proteolytic pathways (16,17,19,31,37). However, the lysosome-mediated degradation of HIF-1α protein also has been proposed (38). Interestingly, there is a previous study implicating the 26S proteasome-independent mechanism of downregulation of HIF-1α protein induced by GS-HCl in DU145 cells (13). In this study, we demonstrate that treatment with MG132 (Fig. 3A, lane 5), but not CQ (lane 6), blocks the repressive effect of short-term GS-HCl treatment on expression of HIF-1α protein in YD-8 cells (lane 4). However, considering that single treatment with MG132 strongly upregulates expression of HIF-1α at protein level in YD-8 cells (lane 2), it is likely that HIF-1α protein downregulation induced by short-term GS-HCl treatment in YD-8 cells herein is the 26S proteasome and lysosome-independent. Several lines of evidence indicate that HIF-1α protein is very labile and its half-life is less than an hour (16,25). In agreement with it, the present study demonstrates that when translation is blocked by CHX, HIF-1α protein induced by serum in YD-8 cells under normoxia is rapidly destabilized regardless of presence or absence of GS-HCl, which may further imply that HIF-1α protein downregulation induced by short-term GS-HCl treatment in YD-8 cells is not mediated through alteration of HIF-1α protein stability.

It has been introduced that glucose is an inducer of HIF-1α expression (accumulation) in human gliomas and other cancer cell lines under normoxia, which requires the metabolism of glucose to pyruvate that prevents the aerobic degradation of HIF-1α protein (39). Furthermore, the same research group has reported that iodoacetate, an inhibitor of glyceraldehyde-3-phosphate dehydrogenase completely blocks the ability of glucose to stimulate aerobic HIF-1α protein accumulation and the replacement of glucose with the citric acid cycle intermediates, such as citrate or 2-oxoglutarate, does not stimulate it. GS is a glucose deprivation mimetic and has been shown to inhibit glycolysis (39,40). It also has been demonstrated that both glucose and GS utilize the same glucose transporter system for import into the cells (41,42), and GS, through inhibition of glucose transporter, interferes with cellular glucose uptake (43). With this in mind, it is assumed that short-term GS-HCl exposure into YD-8 cells may hinder glucose uptake, inhibit glycolysis, and/or produce less (or no) glucose metabolites. In this study, we have shown that HIF-1α protein downregulation by short-term GS-HCl treatment in YD-8 cells is blunted by exogenous administration of citrate or 2-oxoglutarate, but not pyruvate or lactate (Fig. 4). These results strongly suggest a link between HIF-1α protein downregulation and interference of glucose metabolism pathway (particularly production of the citric acid cycle intermediates) in YD-8 cells in response to short-term GS-HCl treatment. An interesting finding in the present study is the specificity of GS-HCl in downregulating HIF-1α at protein level in YD-8 cells, as deduced from that short-term treatment with GS-sulfate or N-acetyl GS does not influence expression of HIF-1α protein in YD-8 cells (Fig. 5).

Because established cancer cell lines are poor indicators of the tumor biology, the pathophysiological relevance of the present findings is unclear at present. Previously, studies have shown that HIF-1α expression is linked to tumor promotion in human OSCC (44) and correlates with the growth and adhesion in human OSCC cells (45). We and others have also recently demonstrated that HIF-1α protein is highly expressed in YD-8 tongue cancer cells (12) and DU145 prostate cancer cells (13), and long-term (24, 48 or 72 h) GS-HCl treatment inhibits proliferation, decreases survival and/or induces apoptosis in YD-8, DU145 and MDA-MB231 breast cancer cells (9,12,13). In view of this, the present study may have importance to address that i) downregulation of HIF-1α protein induced by short-term GS-HCl treatment may facilitate anti-proliferative, antisuavir and pro-apototic effects on YD-8 cells triggered by long-term GS-HCl treatment and ii) short-term treatment with GS-HCl alone and/or in combination with other anti-cancer therapeutics may be useful against OSCC and other malignances in which aberrant expression of HIF-1α protein plays an oncogenic role and/or confers drug resistance.
Collectively, our data demonstrate for the first time that short-term GS-HCl treatment specifically reduces HIF-1α at protein level in YD-8 cells, and the reduction is at least in part associated with interference of the citric acid cycle and/or less production of the citric acid cycle metabolites.

Acknowledgements

We greatly thank Professor Ki-Young Nam for proofreading this manuscript.

References